Research Article

Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis

Yong-Pyo Lee, Min-Sang Lee, Sang Eun Yoon, Junhun Cho, Yeong Hak Bang, Joon Ho Shim, Won Seog Kim, and Seok Jin Kim

1Division of Hematology-Oncology, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
2Division of Oncology/Hematology, Department of Internal Medicine, Soonchunhyang University Hospital Cheonan, Suncheonhyang 6-Gil, Dongnam-gu, Cheonan-si, Chungcheongnam-Do, Republic of Korea
3Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
4Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
5Department of Digital Health, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea
6Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
7Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea

Correspondence should be addressed to Seok Jin Kim; kstwoh@skku.edu

Received 21 May 2022; Revised 6 September 2022; Accepted 8 September 2022; Published 26 September 2022

Academic Editor: Jayaprakash Kolla

Copyright © 2022 Yong-Pyo Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Follicular lymphoma (FL) is considered incurable because remission and relapse are common. Although various salvage treatment options have been proposed, there is no consensus on treatment strategy for FL patients who failed primary treatment. Methods. This single-center study analyzed postevent overall survival (OS) among 70 patients who experienced relapse or progression after rituximab-containing immunochemotherapy according to type of salvage treatment and nature of relapse or progression. Results. Of 70 patients, 42 experienced progression of disease within 24 months (POD24), and six showed disease progression during first-line treatment. Large-cell transformation was found in nine patients with POD24. At the median follow-up of 104 months (95% CI: 90-118 months), POD24 patients experienced significantly worse OS than patients without POD24, and postevent OS was not satisfactory after conventional salvage chemotherapy because the majority of patients relapsed or progressed. However, autologous stem cell transplantation (ASCT) after the first relapse resulted in survival prolongation in patients with POD24. Half of the patients (34/67, 51%) participated in at least one clinical trial during treatment after first relapse, and patients participating in at least one clinical trial irrespective of line of treatment tended to experience better survival. Conclusions. Relapsed or refractory FL patients showed various clinical courses and treatment outcomes according to relapse or progression. Consolidation treatment with ASCT and active participation to clinical trials might prolong survival duration, especially in POD24 cases.

1. Introduction

Follicular lymphoma (FL) is the second most frequent subtype of lymphoma in Western populations, accounting for 35% of all non-Hodgkin lymphomas (NHLs), and is the most common indolent NHL, representing 20%-30% of all cases [1, 2]. For stage I or contiguous stage II patients with FL grade 1/2, involved-site radiotherapy is recommended with curative
intent. However, most patients with FL present as stage III or IV, for which there are no established treatment strategies with curative intent [3]. This is why current treatment guidelines recommend either a “watch and wait” approach for patients with no indications for initiating treatment or encourage participation in clinical trials for patients who are eligible, even with newly diagnosed FL. For patients requiring treatment after diagnosis for conditions such as cytopenia, threatened end-organ function, or symptomatic disease progression, immunochemo-therapy has been used in clinical practice because CD20-targeting monoclonal antibodies such as rituximab and obinutuzumab have shown promising outcomes in combination with cytotoxic chemotherapies. Thus, immunochemo-therapies such as bendamustine plus rituximab (BR) or rituximab plus cyclophosphamide, vincristine, and prednisone with or without doxorubicin (RCHOP or RCVP) are the standard of care for advanced-stage FL patients based on extensive data supporting their efficacy in this setting [4–9]. However, despite the availability of potent frontline treatments, high probability of recurrence including late relapse persists, and prolonged B-cell depletion caused by rituximab could increase the risk of infectious complications [10, 11]. Accordingly, FL is considered a hard-to-cure disease because patients with FL often live longer than those with aggressive B-cell lymphoma due to its indolent nature but eventually die due to disease progression. Additionally, not all patients follow an indolent clinical course, and early disease relapse accompanied by progression of disease within 24 months (POD24) or relapsed disease with large-cell transformation could have aggressive outcomes [12–14]. Various treatment options have been proposed as salvage treatments for FL patients with relapsed or refractory disease. These include anti-CD20 targeted immunotherapy [15], immunochemotherapy [16–18] followed by autologous stem cell transplantation (ASCT) [19], and chemotherapy-free alternatives [20]. Allogeneic stem cell transplantation is also considered a treatment option [21] but is mostly performed in selected patients who are young and fit. However, there has been no consensus on treatment strategies for FL patients who have failed primary treatment, and their outcomes vary depending on the nature of the disease and type of salvage treatment. Therefore, we analyzed the postevent survival outcomes of FL patients who experienced relapse or progression after first-line treatment with BR, RCHOP, or RCVP to address the impacts of subsequent therapies on survival outcomes.

2. Methods

2.1. Patients. In this study, we retrospectively analyzed the survival outcomes of FL patients who experienced any relapse, progression, or any cause of death after primary treatment. The study population was collected from two prospective cohort studies (2008–2011, NCT#00822731 and 2012–2016, NCT#01877109) and the lymphoma registry of Samsung Medical Center between March 2003 and February 2019. The selection criteria are as follows: (1) biopsy-proven grade 1, 2, or 3A FL; (2) received primary systemic immunotherapy for treatment-requiring conditions, such as B symptoms, bulky disease, rapid progressive disease, or advanced-stage disease; (3) experienced an event during or after primary treatment; (4) relapse or progression was determined by computed tomography (CT) scan or positron-emission tomography/CT scan according to the Lugano classification [22]. Thus, we excluded patients who were observed after diagnosis without treatment. Salvage treatment strategies were classified as participation in clinical trials or conventional treatment with cytotoxic chemotherapy with or without CD20 targeting antibody combination. Clinical trials included all experimental treatments using novel agents or new drugs (either alone or in combination with other treatments), and that were conducted in our institution for relapsed or refractory FL patients after provision of informed consent. Conventional chemotherapies were defined as all salvage treatments consisting of cytotoxic chemotherapies, whereas CD20 targeting antibody-containing immunochemoth-erapy included combination chemotherapies with CD20 targeting antibodies such as rituximab.

2.2. Analysis. The objective of this study was to compare postevent survival outcomes according to subsequent salvage treatments. Overall survival (OS) was measured from the date of diagnosis to the date of death by any cause or last follow-up date, whereas postevent OS was measured from the date of first event to the date of death by any cause, and time to next treatment was measured from the date of first event to the date of a second event requiring any type of salvage treatment. To evaluate parameters that could influence outcomes, clinical and laboratory characteristics reflecting disease burden and aggressiveness were collected including Ann Arbor stage, follicular lymphoma international prognostic index (FLIPI) score, number of nodal involvements, bone marrow involvement, and serum lactate dehydrogenase (LDH). Viral marker information was also collected at the time of registration, such as hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc antibody). POD24 was defined as relapse or progression after the first date of primary first-line treatment. As an exploratory analysis, we also compared mutation profiles of tumor tissue at diagnosis with those of rebiopsy tumor tissue after relapse using archived targeted sequencing data that were collected with informed consent as previously described [23, 24]. Mean sequencing coverage was greater than 700×, and somatic alterations were called by a previously described pipeline: MuTect version 1.1.6, Lowfreq version 0.6.1, Pindel version 0.2.5a4 software, and a custom-built in-house algorithm [24–26].

2.3. Statistics. Demographics and patient characteristics were compared by the chi-square test, and the Kaplan-Meier method was used for survival analysis of outcomes. Living patients without second relapse at the time of analysis were censored at the date of last follow-up. The last survival and disease status update was performed in April 2022. The log-rank test was used for comparisons, and all data were analyzed by the Statistical Package for Social Sciences software, version 24.0 (IBM Corp, Armonk, NY, USA).
3. Results

3.1. Events after First-Line Treatment. Seventy patients experienced an event during or after first-line treatment including RCVP \((n = 35)\), RCHOP \((n = 28)\), or BR \((n = 7)\). At the time of first-line treatment, patients had a median age of 44.5 years (range: 29-79 years), and 38 were female. According to FLIPI at diagnosis, 25 patients belonged to the high-risk group (Table 1). At the time of first event, a greater number of patients had high-risk FLIPI scores than at time of diagnosis, and most patients had elevated serum LDH level (Table 1). Two patients were positive for HBsAg, 12 patients had anti-HBc antibodies, and all received prophylactic antiviral agents during and after treatment. Of 70 cases with relapsed or refractory FL, 42 patients experienced POD24, and six of these patients showed disease progression during first-line treatment. Large-cell transformation occurred in nine patients who showed POD24, whereas the remaining 28 patients who relapsed after 24 months did not have large-cell transformation. At the median follow-up of 104 months (95% CI: 90-118 months) after diagnosis, the median OS of the 70 patients who experienced any kind of event was not achieved (Figure 1(a)). However, 15 of 42 patients with POD24 died, whereas only 5 of 28 patients without POD24 died. Accordingly, POD24 patients experienced significantly worse OS than patients without POD24 (Figure 1(b)). Furthermore, the survival outcomes for patients were worst for those experiencing progression within six months after first-line treatment was started. Additionally, the OS of patients who relapsed four years after first-line treatment was not significantly different from that of patients who relapsed from 24 to 48 months (Figure 1(c)).

3.2. Comparison of Outcomes Based on First Salvage Treatment. Among 70 patients, most were initially treated with RCVP \((n = 35)\) or RCHOP \((n = 28)\), while only seven received BR (Table 1). The small number of patients with relapsed or refractory FL after BR was related to the better efficacy of BR as a first-line treatment, as we reported previously [27]. However,

### Table 1: Patient characteristics.

| Parameters                        | At diagnosis | At first event |
|-----------------------------------|--------------|---------------|
| Median (range), years             | 44.5 (29–79) | 52.0 (30–80)  |
| Age                               |              |               |
| ≤60                               | 60 (86%)     | 55 (79%)      |
| >60                               | 10 (14%)     | 15 (21%)      |
| ECOG performance status           |              |               |
| 0/1                               | 65 (93%)     | 65 (93%)      |
| ≥2                                | 5 (7%)       | 5 (7%)        |
| Ann Arbor stage                   |              |               |
| I/II                              | 7 (10%)      | 6 (9%)        |
| III/IV                            | 63 (90%)     | 64 (91%)      |
| Low risk (0–1)                    | 19 (27%)     | 0 (0%)        |
| FLIPI                             |              |               |
| Intermediate risk (2)             | 26 (37%)     | 17 (24%)      |
| High risk (3–5)                   | 25 (36%)     | 53 (76%)      |
| 1                                 | 41 (59%)     | 33 (47%)      |
| 2                                 | 16 (23%)     | 11 (16%)      |
| Large cell transformation         | —            | 9 (13%)       |
| Number of nodal involvements      |              |               |
| ≥5                                | 36 (51%)     | 42 (60%)      |
| <5                                | 34 (49%)     | 28 (40%)      |
| Bone marrow involvement           |              |               |
| Presence                          | 43 (61%)     | Unknown       |
| B-symptoms                        | 4 (6%)       | 3 (4%)        |
| Elevated LDH                      |              |               |
| Presence                          | 19 (27%)     | 67 (96%)      |
| RCVP                              | 35 (50%)     | —             |
| RCHOP                             | 28 (40%)     | 7 (10%)       |
| BR                                | 7 (10%)      | 17 (24%)      |
| Anti-CD20 antibody monotherapy    | —            | 7 (10%)       |
| ICED/ESHAP                        | —            | 18 (26%)      |
| FND                               | —            | 12 (17%)      |
| Other treatments                  | —            | 6 (9%)        |
| Not applicable                    | —            | 3 (4%)        |

ECOG: eastern cooperative oncology group; FLIPI: follicular lymphoma international prognostic index; LDH: lactate dehydrogenase; RCVP: rituximab, cyclophosphamide, vincristine, and prednisone; RCHOP: rituximab, cyclophosphamide, vincristine, prednisone, and doxorubicin; BR: bendamustine and rituximab; ICED: ifosfamide, carboplatin, etoposide, and dexamethasone; ESHAP: etoposide, cisplatin, cytarabine, and methylprednisolone; FND: fludarabine, mitoxantrone, and dexamethasone.
all patients who failed BR showed POD24 (7/7, 100%), whereas approximately half of patients who received RCVP (18/35, 51%) or RCHOP (17/28, 61%) showed POD24. Thus, once relapse occurred, postevent OS was worse in patients receiving BR than in patients who received RCVP or RCHOP (Figure 2(a)). Two patients died due to sepsis associated with febrile neutropenia that occurred after RCVP chemotherapy, and another patient developed B-acute lymphoblastic leukemia as a second malignancy during follow-up. After excluding those three patients, outcomes from subsequent salvage treatments after first relapse were analyzed. Salvage treatment types for first relapses were divided as follows: (1) BR, (2) RCHOP, (3) CD20-directed monotherapies such as rituximab and ofatumumab, (4) ICED (ifosfamide, carboplatin etoposide, and dexamethasone) or ESHAP (etoposide, cisplatin, cytarabine, and methylprednisolone), (5) FND (fludarabine, mitoxantron, and dexamethasone), and (6) other treatments including PI3K (phosphoinositide 3-kinase) inhibitors or HDAC (histone deacetylase) inhibitors (Table 1). When postevent OS was compared by salvage treatment type, patients receiving RCHOP had the worst OS because they were mainly early relapsed patients after BR (Figure 2(b)). However, patients receiving BR, ICED/ESHAP, and FND also eventually showed relapse or progression, and 72% of patients (48/67) had secondary events requiring additional salvage treatments. The time to next treatment was similar among all patients except those receiving CD20-directed monotherapies such as rituximab and ofatumumab (Figure 2(c)). After the first event, ASCT was performed for 14 patients who responded to salvage chemotherapy. Of 42 patients with POD24, 11 underwent ASCT after first relapse, and their postevent OS was better than that of the 31 patients who did not receive ASCT after POD24,
although the difference was not statistically significant (Figure 3(a)). During the treatment journey after first relapse, half of patients (34/67, 51%) participated in at least one clinical trial. When postevent OS was compared by participation in clinical trials, patients participating in at least one clinical trial, irrespective of treatment line, had better survival than patients who did not, although the difference was not statistically significant (Figure 3(b)). Seven of 14 HBsAg- or anti-HBc antibody-positive patients participated in clinical trials and had a better survival trend than patients who did not (Figure 3(c)).

3.3. Postevent Outcomes for Patients with Multiple Events. After 48 patients experienced a second relapse after their first salvage treatment, they were treated with additional salvage treatments. However, despite salvage treatment, 34 patients experienced more than two episodes of relapse or progression. Postevent overall survival was significantly worse in patients who experienced more than two relapses than in patients who did not (Figure 4(a)). During the clinical course, large-cell transformation was histologically confirmed in nine patients, and secondary central nervous system (CNS) involvement was found in five; postevent OS of these patients with large-cell transformation or secondary CNS involvement was significantly worse than in patients without it (Figure 4(b)). However, age at the time of first relapse was not associated with postevent overall survival, suggesting that patients older than 60 years could be rescued by subsequent treatments (Figure 4(c)). When we compared the mutation profiles from diagnosis with those from relapse or progression using paired tumor samples from four patients, truncated or nontruncated mutations were frequently found in CREBBP and BCL2 at the time of diagnosis and relapse (Figure 5(a)). In case #1, a 57-year-old female with grade 1 disease, stage III FL became refractory to RCVP (Figure 5(b)). However,
rebiopsy of the lesion revealed grade I, and the comparison of mutation profiles demonstrated no additional mutations (Figure 5(a)). She received platinum-based ICED and maintained complete response after ASCT. In contrast, a 39-year-old male (case #2) progressing during BR showed large-cell transformation and additional changes including deletion of GNA13 (Figure 5(a) and 5(c)). He was refractory to subsequent salvage treatments and eventually died due to disease progression. A 40-year-old male (case #3) showed localized relapse with no systemic symptoms during follow-up after RCHOP and rituximab maintenance (Figure 5(d)). The rebiopsy of the lesion showed grade I and was same as that of his initial diagnosis, and the mutation profiles were not significantly different (Figure 5(a)). He was successfully managed with radiation therapy. A 49-year-old female with FL grade II (case #4) relapsed after RCHOP, and the rebiopsy showed grade II and no significant changes in mutation profile at the time of relapse (Figure 5(a)). Her disease status was rescued by participating in a trial with ibrutinib-containing chemotherapy (Figure 5(e)).

4. Discussion

In this study, we retrospectively analyzed survival outcomes of FL patients who relapsed or progressed after first-line treatment with rituximab-containing chemotherapy including RCHOP, RCVP, or BR to evaluate the impact of subsequent salvage therapies on prognosis. Although all patients experienced at least one event after their first-line treatment, OS did not reach the median value at the median follow-up of 104 months (95% CI: 90-118 months) after diagnosis, which highlights the indolent nature of FL (Figure 1(a)). Nevertheless, 15 of 42 patients...
who had an early event—so called POD24—died, whereas only five of 28 patients who relapsed after 24 months died. A recent pooled analysis of 13 clinical trials validated POD24 as a significant prognostic indicator for poor survival in FL patients, and our study also observed poorer survival outcomes for patients with POD24 regardless of type of frontline and salvage treatment (Figure 1(b)) [28]. Of 70 patients with relapsed or refractory FL in our study, the majority was treated with RCVP ($n = 35$) or RCHOP ($n = 28$) rather than BR ($n = 7$). However, although the absolute number of relapses or progressions was lower among patients receiving BR than RCVP or RCHOP, all patients who relapsed or progressed after BR had an early event. This was consistent with the relatively higher incidence of early progression during or after BR therapy in a population-based cohort of FL patients [29].

The BR regimen has been widely used as a frontline treatment for newly diagnosed FL patients due to its superior outcomes to RCVP and RCHOP in terms of progression-free survival and toxicity profiles [30, 31]. Accordingly, if FL patients were initially not treated with anthracycline-containing chemotherapy, they could be treated with CHOP-like regimens such as obinutuzumab-CHOP (GCHOP) [27]. However, our patients who initially received BR were treated with conventional chemotherapy such as ICED or FND because the GCHOP regimen was not available in Korea. Furthermore, RCHOP could be used only for patients who had large-cell transformation. Accordingly, postevent OS after the first relapse or progression was shortest in patients receiving RCHOP, while the outcomes for patients receiving BR, ICED, and FND were not significantly different (Figure 2(b)). Additionally, because most patients relapsed after these salvage treatments, the time to next treatment was not different except for patients receiving anti-CD20 monoclonal antibody alone such as rituximab or ofatumumab monotherapy (Figure 2(c)). The superior outcomes for patients receiving

---

**Figure 4:** (a) Comparison of postevent overall survival according to number of relapses. (b) Comparison of postevent overall survival by occurrence of large-cell transformation or secondary central nervous system involvement. (c) Age at time of first relapse was not associated with postevent overall survival.
Figure 5: Continued.
anti-CD20 monoclonal antibody alone were associated with the indolent nature of their tumors because rituximab or ofatumumab monotherapy was only used for patients with less aggressive symptoms and low tumor burden in our clinical practice.

For relapsed or refractory FL patients, particularly those with POD24, high-dose chemotherapy followed by ASCT has been proposed as a consolidative treatment [32]. However, ASCT could not be performed in all cases because patients who are candidates for this treatment are young, otherwise healthy, and should achieve complete or partial response after salvage therapy. Accordingly, not all patients underwent ASCT in our study, and only 14 underwent ASCT after their first relapse. Because the number of patients undergoing ASCT was relatively small, postevent OS of patients receiving ASCT was not significantly different from that of patients who did not receive it and who experienced POD24 (Figure 3(a)). However, given the trend of better survival outcomes in the ASCT group, consolidation treatment with ASCT could be...
considered for patients responding to salvage treatment, especially in cases of early relapse or progression. In our study, half of the patients (34/67, 51%) participated in at least one clinical trial during their treatment after first relapse. The patients participating in at least one clinical trial experienced better survival than those who did not, although the difference was not statistically significant (Figure 3(b)). However, this result could be due to selection bias because only patients with adequate organ function and performance status can be enrolled in clinical trials. Nevertheless, patients should always be recommended to participate in clinical trials because postevent OS and time to next treatment after conventional salvage chemotherapies were not satisfactory (Figure 2(b) and 2(c)). In B-cell lymphoid malignancies, in which anti-CD20 antibodies are essential treatment components, close to 10% of patients with positive HBsAg- or anti-HBc antibodies experienced reactivation of hepatitis B virus (HBV) [33]. Thus, HBsAg- or anti-HBc antibody-positive patients in general were excluded as candidates for clinical trials. In this study, participation in clinical trials was associated with better survival outcomes for even HBsAg- or anti-HBc antibody-positive patients although the sample size was small (Figure 3(c)). Considering that prophylactic antiviral agents and periodic HBV DNA monitoring are routinely performed in clinical practice, thoughtful consideration should be given to the potential inclusion of patients with HBV in clinical trials.

We conducted genomic analysis using paired tumor tissue samples at diagnosis and relapse and observed frequent occurrence of mutations in CREBBP and EZH2, which are involved in lymphomagenesis and progression as a chromatin regulator, as well as mutations in BNFRSF14 and BCL2 as previously reported [34]. Interestingly, the mutations observed at diagnosis and relapse were similar, although the number was too small for statistical analysis (Figure 4(c)). However, a case with large-cell transformation showed that occurrence of additional genomic alterations are consistent with worse survival outcomes (Figure 4(b)). In our study, patients who experienced repeated multiple relapses had worse survival outcomes than those who did not (Figure 4(a)). Furthermore, most patients eventually relapsed even after ASCT and other additional treatments including participation in clinical trials. Therefore, considering the final outcomes as well as quality of life of patients who experienced repeated relapses, more efficient treatment approaches are needed, such as chimeric antigen receptor (CAR) T-cells, for which favorable outcomes have been reported [35–37].

However, our study has some limitations as follows. First, the number of patients who were analyzed in this study was too small because FL is relatively uncommon in Korea compared to Western countries, and this was a single-center analysis. Accordingly, our survival analysis failed to reach statistically significant values in the comparison of survival outcomes based on various parameters such as participating in clinical trials and age at the time of first relapse. Furthermore, as our patients received various salvage treatments and had variable clinical conditions at the time of relapse or progression, there were many factors potentially influencing survival outcome after relapse or progression. That was why we could not conduct multivariate analysis for identification of risk factors predicting outcome of FL patients after relapse. Thus, further study with larger population should be warranted to establish a prognostic model for relapsed or refractory FL patients. Second, due to the retrospective nature of this study, several clinically important issues could not be addressed such as the occurrence of deep vein thrombosis (DVT) and pulmonary thromboembolism (PE) although FL patients might be at risk of DVT and PE in clinical practice [38, 39]. In addition, most patients received various salvage treatments including participation in clinical trials. Thus, there might be some potential effects of drug-drug interactions on the outcome of patients as previously reported [40, 41]. However, those issue could not be addressed, either because there were no data available for analyzing them. Given the importance of those factors, further more detailed studies also might be required.

In conclusion, although the sample size of our study was relatively small, we evaluated patient survival outcomes after relapse or progression during or after first-line treatment. Due to the poor outcomes of patients with POD24, high-dose chemotherapy followed by ASCT should be considered for patients with chemotherapy-sensitive relapse. Additionally, participation in clinical trials should be considered during any point in the clinical course of relapse or refractory FL. However, given the unmet needs of relapsed or refractory FL patients, novel therapies such as CAR T-cells should be more actively used to improve outcomes of FL patients in terms of relapse prevention.

Data Availability
All of the data analyzed are included in this published article. The datasets collected during the study are available from the corresponding author on reasonable request.

Ethical Approval
The study was approved by the Institutional Review Board of Samsung Medical Center (IRB number 2019-11-081).

Disclosure
The authors are fully responsible for the contents of this manuscript, and the views and opinions described in the publication are solely those of the authors.

Conflicts of Interest
The author(s) declare(s) that they have no conflicts of interest.

Authors’ Contributions
YPL, MSL, and SJK wrote the manuscript. YHB and JHS performed targeted sequencing and analysis. YPL, MSL, SEY, WSK, and SJK analyzed the data. SEY, WSK, and SJK reviewed the clinical data. JC reviewed the pathology, and SJK designed the study. Yong-Pyo Lee, Min-Sang Lee. These two authors contributed equally as co-first authors.
Acknowledgments

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI22C0999).

References

[1] S. H. Swerdlow, E. Campo, S. A. Pileri et al., "The 2016 revision of the World Health Organization classification of lymphoid neoplasms," Blood, vol. 127, no. 20, pp. 2375–2390, 2016.

[2] L. R. Teras, C. E. DeSantis, J. R. Cerhan, L. M. Morton, A. Jemal, and C. R. Flowers, "2016 US lymphoid malignancy statistics by World Health Organization subtypes," CA: a Cancer Journal for Clinicians, vol. 66, no. 6, pp. 443–459, 2016.

[3] M. Dreyling, M. Ghielmini, S. Rule et al., "Locally advanced and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up," Annals of Oncology, vol. 27, supplement 5, pp. v83–v90, 2016.

[4] W. Hiddemann, M. Kneba, M. Dreyling et al., "Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group," Blood, vol. 106, no. 12, pp. 3725–3732, 2005.

[5] R. Marcus, K. Imrie, P. Solal-Celigny et al., "Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma," Journal of Clinical Oncology, vol. 26, no. 28, pp. 4579–4586, 2008.

[6] M. J. Rummel, N. Niederle, G. Maschmeyer et al., "Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial," Lancet, vol. 381, no. 9873, pp. 1203–1210, 2013.

[7] H. Schulz, J. F. Bohlius, S. Trelle et al., "Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis," Journal of the National Cancer Institute, vol. 99, no. 9, pp. 706–714, 2007.

[8] R. Marcus, A. Davies, K. Ando et al., "Obinutuzumab for the first-line treatment of follicular lymphoma," New England Journal of Medicine, vol. 377, no. 14, pp. 1331–1344, 2017.

[9] I. W. Flinn, R. van der Jagt, B. S. Kahl et al., "Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study," Blood, vol. 123, no. 19, pp. 2944–2952, 2014.

[10] A. Rashidi, E. Oak, and N. L. Bartlett, "Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma," Blood, vol. 125, no. 21, pp. 3354-3355, 2015.

[11] L. Vidal, A. Gafter-Gvili, G. Salles et al., "Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials," Journal of the National Cancer Institute, vol. 103, no. 23, pp. 1799–1806, 2011.

[12] C. Casulo, M. Byrtrek, K. L. Dawson et al., "Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study," Journal of Clinical Oncology, vol. 33, no. 23, pp. 2516–2522, 2015.

[13] E. Giné, S. Montoto, F. Bosch et al., "The follicular lymphoma international prognostic index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma," Annals of Oncology, vol. 17, no. 10, pp. 1539–1545, 2006.

[14] S. E. Yoon, J. Cho, W. S. Kim, and S. J. Kim, "Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months," Journal of Cancer, vol. 12, no. 9, pp. 2488–2497, 2021.

[15] G. Martinelli, S.-F. H. Schmitz, U. Utiger et al., "Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98," Journal of Clinical Oncology, vol. 28, no. 29, pp. 4480–4484, 2010.

[16] M. H. van Oers, R. Klasa, R. E. Marcus et al., "Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial," Blood, vol. 108, no. 10, pp. 3295–3301, 2006.

[17] J. Radford, A. Davies, G. Carton et al., "Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000),” Blood, vol. 122, no. 7, pp. 1137–1143, 2013.

[18] B. D. Cheson, N. Chua, J. Mayer et al., "Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received Obinutuzumab plus Bendamustine induction and Obinutuzumab maintenance in the GADOLIN study," Journal of Clinical Oncology, vol. 36, no. 22, pp. 2259–2266, 2018.

[19] A. Z. Rohatiner, L. Nadler, A. J. Davies et al., "Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remissions: long-term follow-up," Journal of Clinical Oncology, vol. 25, no. 18, pp. 2554–2559, 2007.

[20] J. P. Leonard, S. H. Jung, J. Johnson et al., "Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (alliance),” Journal of Clinical Oncology, vol. 33, no. 31, pp. 3635–3640, 2015.

[21] K. van Besien, F. R. Loberiza Jr., and R. Bajorunaite, "Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma," Blood, vol. 102, no. 10, pp. 3521–3529, 2003.

[22] B. D. Cheson, R. I. Fisher, S. F. Barrington et al., "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification," Journal of Clinical Oncology, vol. 32, no. 27, pp. 3059–3067, 2014.

[23] J. Hyeon, B. Lee, S. H. Shin et al., "Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of _TRAF3_ and _TNFAIP3_ that were mutually exclusive for _MALT1_ rearrangement,” Modern Pathology, vol. 31, no. 9, pp. 1418–1428, 2018.

[24] H. T. Shin, Y. L. Choi, J. W. Yun et al., "Prevalence and detection of low-allele-fraction variants in clinical cancer samples," Nature Communications, vol. 8, no. 1, p. 1377, 2017.
[25] A. Wilm, P. P. Aw, D. Bertrand et al., “LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets,” *Nucleic Acids Research*, vol. 40, no. 22, pp. 11189–11201, 2012.

[26] K. Cibulskis, M. S. Lawrence, S. L. Carter et al., “Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples,” *Nature Biotechnology*, vol. 31, no. 3, pp. 213–219, 2013.

[27] C. Casulo and P. M. Barr, “How I treat early-relapsing follicular lymphoma,” *Blood*, vol. 133, no. 14, pp. 1540–1547, 2019.

[28] C. Casulo, J. G. Dixon, J. Le-Rademacher et al., “Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials,” *Blood*, vol. 139, no. 11, pp. 1684–1693, 2022.

[29] C. L. Freeman, R. Kridel, A. A. Moccia et al., “Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma,” *Blood*, vol. 134, no. 9, pp. 761–764, 2019.

[30] I. W. Flinn, R. van der Jagt, B. Kahl et al., “First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with Bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study,” *Journal of Clinical Oncology*, vol. 37, no. 12, pp. 984–991, 2019.

[31] P. Mondello, N. Steiner, W. Willenbacher et al., “Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: evidence from a Multicenter, Retrospective Study,” *Retrospective Study. Oncologist*, vol. 23, no. 4, pp. 454–460, 2018.

[32] H. C. Schouten, W. Qian, S. Kvaloy et al., “High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial,” *Journal of Clinical Oncology*, vol. 21, no. 21, pp. 3918–3927, 2003.

[33] C. Hsu, H. H. Tsou, S. J. Lin et al., “Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study,” *Hepatology*, vol. 59, no. 6, pp. 2092–2100, 2014.

[34] J. Okosun, C. Bödör, J. Wang et al., “Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma,” *Nature Genetics*, vol. 46, no. 2, pp. 176–181, 2014.

[35] A. V. Hirayama, J. Gauthier, K. A. Hay et al., “High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy,” *Blood*, vol. 134, no. 7, pp. 636–640, 2019.

[36] J. N. Kochenderfer, W. H. Wilson, J. E. Janik et al., “Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19,” *Blood*, vol. 116, no. 20, pp. 4099–4102, 2010.

[37] S. J. Schuster, J. Svoboda, E. A. Chong et al., “Chimeric antigen receptor T cells in refractory B-cell lymphomas,” *The New England Journal of Medicine*, vol. 377, no. 26, pp. 2545–2554, 2017.

[38] S. Hohaus, F. Bartolomei, A. Cuccaro et al., “Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis,” *Cancers (Basel)*, vol. 12, no. 5, p. 1291, 2020.

[39] A. Datta, M. K. Matlock, N. Le Dang et al., “Black box to ‘conversational’ machine learning: ondansetron reduces risk of hospital-acquired venous thromboembolism,” *IEEE Journal of Biomedical and Health Informatics*, vol. 25, no. 6, pp. 2204–2214, 2021.

[40] A. Datta, N. R. Flynn, D. A. Barnette, K. F. Woeltje, G. P. Miller, and S. J. Swamidass, “Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort,” *PLoS Computational Biology*, vol. 17, no. 7, article e1009053, 2021.

[41] M. Darwish, J. M. Burke, E. Hellriegel et al., “An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma,” *Cancer Chemotherapy and Pharmacology*, vol. 73, no. 6, pp. 1119–1127, 2014.